Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Carmelo Carlo-Stella, MD, Pier Luigi Luigi Zinzani, MD, Brad S. Kahl, MD, Paolo F Caimi, MD, Melhem Solh, MD, William Townsend, MRCP,MDFRCPath, Anastasios Stathis, MD, Elizabeth H. Cull, MD, Mehdi Hamadani, MD, Alexander I. Spira, PhD MD FACP, Jay Feingold, MD PhD, David Ungar, MD, Shui He, PhD, Yajuan Qin, John Radford

Blood (2019) 134 (Supplement_1): 757.

https://doi.org/10.1182/blood-2019-128401

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5309.

https://doi.org/10.1182/blood-2019-126913

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

John Radford, MD FRCP, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Paolo Caimi, MD, Kirit M. Ardeshna, MBBChir, Jay Feingold, MD PhD, Shui He, PhD, Erin Reid, MD, Melhem Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, David Ungar, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 398.

https://doi.org/10.1182/blood-2018-99-116081

Published: 2018

Journal Articles

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Paolo Caimi, MD, Brad S. Kahl, MD, Mehdi Hamadani, MD, Carmelo Carlo-Stella, MD, Shui He, PhD, David Ungar, MD, Jay Feingold, MD PhD, Kirit M. Ardeshna, MA MD FRCP FRCPath, John Radford, MD FRCP, Melhem Solh, MD, Leonard Heffner, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2018-99-118133

Published: 2018

Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2662.

https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662

Published: 2017

Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt

Blood (2017) 130 (Supplement 1): 1321.

https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321

Published: 2017

Journal Articles

Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data

Anissa Cyaniuk, MS, David L. Cooper, MD, MBA, Desiree Hall, MS, David Ungar, MD, Chioma Smith, MPH, Tami Wisniewski, MPH

Blood (2013) 122 (21): 2947.

https://doi.org/10.1182/blood.V122.21.2947.2947

Published: 2013

NARROW

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only